• Intellipharmaceutics International Inc., of Toronto, said it reached an agreement with London-based AstraZeneca plc to settle all outstanding patent litigation concerning its abbreviated new drug application to commercialize a generic version of AstraZeneca's Seroquel XR (quetiapine fumarate extended-release) tablets. The settlement provides, in part, that the company is permitted to launch generic versions on Nov. 1, 2016, or earlier under certain circumstances, subject to FDA approval.